Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

Study provides clues to improve treatment of neuroblastoma with suppressor gene

Loss of a gene required for stem cells in the brain to turn into neurons may underlie the most severe forms of neuroblastoma, a deadly childhood cancer of the nervous system, according to a Ludwig Cancer Research study.

13 Aug 2013

Researchers explore potential of neural stem cells to repair brain damage

Scientists have long believed that healthy brain cells, once damaged by radiation designed to kill brain tumors, cannot regenerate. But new Johns Hopkins research in mice suggests that neural stem cells, the body’s source of new brain cells, are resistant to radiation, and can be roused from a hibernation-like state to reproduce and generate new cells able to migrate, replace injured cells and potentially restore lost function.

13 Aug 2013

NW Bio receives decision to continue Phase III clinical trial on brain cancer in Germany

Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received a decision from the German regulatory agency (the Paul Ehrlich Institute, or PEI) under which the Company's Phase III clinical trial will be able to proceed in Germany after the Company makes three modifications, none of which affect the body of the trial or the bases for seeking product approval.

12 Aug 2013

Understanding the movement of neurons sheds light on how cancer cells invade health tissues

The invasion of brain-tumor cells into surrounding tissue requires the same protein molecule that neurons need to migrate into position as they differentiate and mature, according to new research from the University of Illinois at Chicago College of Medicine and published August 7 in the online journal PLOS ONE.

8 Aug 2013

Brain tumor cells in arrested development contribute to cell variety that protects cancer

A program that pushes immature cells to grow up and fulfill their destiny as useful, dedicated cells is short-circuited in the most common and deadly form of brain tumor, scientists at The University of Texas MD Anderson Cancer Center report this week in the Early Edition of the Proceedings of the National Academy of Sciences.

8 Aug 2013

Columbia researchers identify 18 new genes that drive glioblastoma multiforme

A team of researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center has identified 18 new genes responsible for driving glioblastoma multiforme, the most common-and most aggressive-form of brain cancer in adults. The study was published August 5, 2013, in Nature Genetics.

6 Aug 2013

Novocure uses NovoTTF therapy to treat first recurrent glioblastoma tumor patient

Novocure today announced that Dr. Tatsunori Okamaura, MD, Ph.D., of the Kashiwaba Neurosurgical Hospital in Sapporo, Japan has treated the first patient in Japan with alternating electric field therapy.

1 Aug 2013

ImmunoCellular initiates ICT-121 phase I trial in patients with recurrent glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd. today announced initiation of a phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme.

30 Jul 2013

3-D hydrogel approach to study aggressive and deadly forms of brain cancer

Human glioblastoma multiforme, one of the most common, aggressive and deadly forms of brain cancer, is notoriously difficult to study. Scientists have traditionally studied cancer cells in petri dishes, which have none of the properties of the brain tissues in which these cancers grow, or in expensive animal models.

24 Jul 2013

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier and kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

19 Jul 2013

CUMC researchers develop new approach to tailor cancer therapy for individual patient

Columbia University Medical Center (CUMC) researchers are developing a new approach to cancer clinical trials, in which therapies are designed and tested one patient at a time.

16 Jul 2013

GAPVAC aims to develop personalized therapeutic vaccines for cancer

A highly innovative project supported by a €6 million European Union Framework 7 (EU FP7) program grant to develop a novel class of therapeutic cancer vaccines is now under way.

4 Jul 2013

Professor receives grant to explore therapeutic agent, treatment method for brain cancer

The problem with cancer treatments designed to kill a tumor is that they can kill the patient's quality of life as well. Now a Florida State University College of Medicine researcher is shifting the focus from eradicating brain tumors to managing them.

4 Jul 2013

UVA researchers identify promising target for treating glioblastoma

Researchers at the University of Virginia Cancer Center have identified a promising target for treating glioblastoma, one that appears to avoid many of the obstacles that typically frustrate efforts to develop effective treatments for this deadliest of cancers.

2 Jul 2013

Investigators uncover connection between tumor metabolic process and progression of kidney cancer

Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC).

24 Jun 2013

Combination therapy with myxoma virus and rapamycin can kill glioblastoma multiforme

A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to Moffitt Cancer Center research.

21 Jun 2013

Signaling pathway correlates with EGFR status and poor survival in breast cancer patients

Researchers have discovered and mapped the signaling network between two previously unconnected proteins, exposing a link that, if broken, could cut off cancer cell growth at its starting point.

19 Jun 2013

UCSC experts awarded $3.5M NIH grant to develop cancer genomics tools

Despite some successes, predicting cancer outcomes based on the molecular signatures in cancer cells remains a major challenge. A new effort, funded by the National Cancer Institute and led by researchers at the University of California, Santa Cruz, aims to clear several key roadblocks that have stymied progress in this field.

18 Jun 2013

Abnormal metabolic pathway drives cancer-cell growth in glioblastoma subtype

A study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has identified an abnormal metabolic pathway that drives cancer-cell growth in a particular glioblastoma subtype. The finding might lead to new therapies for a subset of patients with glioblastoma, the most common and lethal form of brain cancer.

14 Jun 2013

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced clinical data demonstrating the utility of VB-111's in targeted cancer treatment.

3 Jun 2013